Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

153
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
153
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.2K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.2K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

86
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
86
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

131
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
131
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

118
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
118
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

131
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
131

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Gender Authorship in Gastroenterology and Hepatology: Trends and Persistent Seniority Gaps.

Journal of gastroenterology and hepatology·2026
Same author

AI counseling agent for motivational interviewing: Conversational processes associated with change talk in emergency department patients.

Journal of substance use and addiction treatment·2026
Same author

TFG-Containing Fusions in Melanocytic Tumors: From Polymorphic Read-Through Transcripts to Oncogenic Kinase Fusions.

Journal of cutaneous pathology·2026
Same author

Immunometabolic remodeling of perivascular adipose tissue in murine lupus: implications for lupus vasculopathy.

bioRxiv : the preprint server for biology·2026
Same author

A unified physiologically based pharmacokinetic model for low-to-high oral, subcutaneous, and intravenous dose of methotrexate in humans.

Journal of pharmaceutical sciences·2026
Same author

Developing a Clinically Practical Biomaterial Platform for Endogenous Liver Regeneration.

Gels (Basel, Switzerland)·2026

相关实验视频

Updated: Sep 17, 2025

Topical Application Bioassay to Quantify Insecticide Toxicity for Mosquitoes and Fruit Flies
09:37

Topical Application Bioassay to Quantify Insecticide Toxicity for Mosquitoes and Fruit Flies

Published on: January 19, 2022

6.2K

一个基于生理学的动力模型,用于量化人类对DEET的暴露.

Min-Soo Kim1, Abdullah Hamadeh1, Jason Kowalski2

  • 1School of Pharmacy, University of Waterloo, 10A Victoria Street South, Kitchener, Ontario, N2G 1C5, Canada.

International journal of hygiene and environmental health
|June 29, 2025
PubMed
概括

一个基于N,N-二甲基-3-甲基胺 (DEET) 和其代谢物的药理动力学模型 (PBK) 已开发并在人类中验证. 该模型有助于估计DEET暴露,并评估使用驱虫剂的儿童的安全性.

关键词:
生物可用性 生物可用性孩子 孩子 孩子 孩子DCBA DCBA DCBA 的意思是什么意思迪特·迪特 (Deet Deet) 是一个著名的演员.驱虫剂是一种驱虫剂.在PBPK建模中使用PBPK模型.风险评估 风险评估 风险评估

更多相关视频

An Air-liquid Interface Bronchial Epithelial Model for Realistic, Repeated Inhalation Exposure to Airborne Particles for Toxicity Testing
09:29

An Air-liquid Interface Bronchial Epithelial Model for Realistic, Repeated Inhalation Exposure to Airborne Particles for Toxicity Testing

Published on: May 13, 2020

11.8K
Electrophysiological Recording of The Central Nervous System Activity of Third-Instar Drosophila Melanogaster
06:45

Electrophysiological Recording of The Central Nervous System Activity of Third-Instar Drosophila Melanogaster

Published on: November 21, 2018

11.7K

相关实验视频

Last Updated: Sep 17, 2025

Topical Application Bioassay to Quantify Insecticide Toxicity for Mosquitoes and Fruit Flies
09:37

Topical Application Bioassay to Quantify Insecticide Toxicity for Mosquitoes and Fruit Flies

Published on: January 19, 2022

6.2K
An Air-liquid Interface Bronchial Epithelial Model for Realistic, Repeated Inhalation Exposure to Airborne Particles for Toxicity Testing
09:29

An Air-liquid Interface Bronchial Epithelial Model for Realistic, Repeated Inhalation Exposure to Airborne Particles for Toxicity Testing

Published on: May 13, 2020

11.8K
Electrophysiological Recording of The Central Nervous System Activity of Third-Instar Drosophila Melanogaster
06:45

Electrophysiological Recording of The Central Nervous System Activity of Third-Instar Drosophila Melanogaster

Published on: November 21, 2018

11.7K

科学领域:

  • 毒理学 毒理学 毒理学
  • 药理动力学 药理动力学
  • 环境健康 环境健康

背景情况:

  • N,N-二甲基-3-甲基胺 (DEET) 是用于对抗蚊子和的昆虫驱虫剂的关键成分.
  • 对DEET及其主要代谢物3 - - 甲基基酸 (DCBA) 开发了一种基于人体药理动力学 (PBK) 的模型.

研究的目的:

  • 开发和验证人类PBK模型的DEET和DCBA.
  • 解释儿童DEET暴露研究中的生物监测数据.

主要方法:

  • 对于DEET和DCBA的综合系统和机械皮肤吸收模型.
  • 利用体外,体内和体内数据用于模型开发和优化.
  • 根据人类药理动力学和生物监测研究数据验证的模型预测.

主要成果:

  • 集成的PBK模型准确地预测了尿中DEET度在2倍的范围内.
  • 据估计,夏令营中典型的DEET应用量为24小时内69.0毫克,皮肤生物利用率为24.2%.
  • 模拟的DEET时间过程概况与已公布的药理动力学数据保持一致.

结论:

  • 通过使用集成数据,成功开发了对DEET和DCBA的验证的人类PBK模型.
  • 该模型允许估计外部DEET剂量,并证实了超过关注水平的暴露幅度.